House com­mit­tees kick off in­ves­ti­ga­tion in­to how Bio­gen's Aduhelm won ap­proval

Two key House com­mit­tees — on Over­sight and Re­form, and En­er­gy and Com­merce — have now of­fi­cial­ly opened their own in­ves­ti­ga­tion in­to the ap­proval of Bio­gen’s new Alzheimer’s drug Aduhelm by ask­ing the com­pa­ny for a va­ri­ety of dif­fer­ent in­ter­nal and ex­ter­nal doc­u­ments and com­mu­ni­ca­tions re­lat­ing to as­sess­ments of the drug’s safe­ty, ef­fi­ca­cy, or clin­i­cal ben­e­fit.

The com­mit­tees are specif­i­cal­ly tar­get­ing the way in which the FDA used the ac­cel­er­at­ed ap­proval path­way to sign off on Aduhelm, de­spite not ques­tion­ing its pan­el of out­side ex­perts (three of whom have since re­signed) on whether such an ac­cel­er­at­ed ap­proval would be ap­pro­pri­ate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.